Laurus Labs Ltd approves USD 3.75 million investment to acquire 60% of Galenvs Sciences
- Investment comprises a USD 2.75 million primary subscription and USD 1.00 million secondary share purchase, at a USD 3.50 million pre-money valuation.
- Montréal-based Galenvs is a CRO/CDMO focused on custom oligonucleotide synthesis and magnetic-nanoparticle technologies; it reported CY2025 turnover of CAD 1.65 million.
- Completion is expected during the current financial year, subject to customary closing conditions.